Machina Capital S.A.S. acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,114 shares of the medical research company's stock, valued at approximately $1,254,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. American National Bank & Trust bought a new position in shares of IQVIA in the first quarter worth approximately $26,000. Golden State Wealth Management LLC grew its stake in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new position in shares of IQVIA in the 1st quarter worth $33,000. ST Germain D J Co. Inc. raised its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA during the 4th quarter worth $39,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Trading Down 0.8%
IQV stock traded down $1.65 on Friday, reaching $199.17. The company's stock had a trading volume of 2,138,911 shares, compared to its average volume of 2,283,775. The firm has a market cap of $33.86 billion, a PE ratio of 28.82, a PEG ratio of 2.21 and a beta of 1.30. The business has a fifty day simple moving average of $155.96 and a two-hundred day simple moving average of $170.53. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.82 and a current ratio of 0.84.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period last year, the company posted $2.64 EPS. The company's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Analyst Upgrades and Downgrades
IQV has been the topic of a number of research analyst reports. HSBC cut IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Redburn Partners set a $188.00 price objective on IQVIA in a report on Friday, May 23rd. Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday. Finally, Truist Financial increased their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday. Seven research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.
Read Our Latest Report on IQVIA
Insider Buying and Selling
In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
